WaveMan
WaveMan · Company
RGC · Regencell Bioscience Holdings Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

RGC Regencell Bioscience (RGC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001829667
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter

Regencell Bioscience insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Regencell Bioscience Holdings Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 7.3 days to cover · settled 2026-09-30
below 88% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RGC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.3%12M
-70%+32%+134%+236%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RGC: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
422,011 sh
$2.6M
Alyeska Investment Group, L.P.
416,261 sh
$2.5M
Legal & General Group Plc
128,000 sh
$779.0K
JANE STREET GROUP, LLC
98,348 sh
$598.9K
XTX Topco Ltd
60,061 sh
$365.8K

Congress trades in RGC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RGC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RGC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P Emerging Markets Momentum ETF
$3.0K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RGC financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.22x
current debt only, 2021-02-21; equity 2026-06-30
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$3.8B
market value at close 2026-10-23 on 2026-06-30 shares, plus current debt only, 2021-02-21, minus cash 2022-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Operating income-$11.7M-$3.8M-$4.7M-$6.3M
Net income-$11.7M-$3.6M-$4.3M-$5.9M
EPS (diluted)n/a-0.72-0.87n/a
Operating cash flow-$7.7M-$3.1M-$4.0M-$5.0M
SEC XBRL, fiscal years, as known on 2026-10-27

RGC Stock Sonar score 3/7 axes

Find similar shapesCompare

RGC ranks highest on risk and compliance (79th percentile) and financial health (42nd), and lowest on institutional and government (37th), among Pharma & Biotech peers.

Financial health
42
Inputs
  • Debt to equity0.22x · 42 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Institutional and government
37
Inputs
  • Funds adding, latest quarter27 · 37 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
79
Inputs
  • Short interest, % of float+1.2% · 79 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies